NASDAQ · ACRS
Aclaris Therapeutics, Inc.
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
Loading market information…
NYSE · OMI · USD
Stock price, dividends, earnings
Quote as of Jan 12, 2026, 02:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Owens & Minor, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Owens & Minor, Inc.’s forward annual dividend is $0.01 per share, paid quarterly. The forward yield is 0.3% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Owens & Minor, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Owens & Minor, Inc., along with its affiliated entities, operates as a global provider of healthcare solutions, serving markets both within the United States and internationally. Its business is structured into two primary divisions: Global Solutions and Global Products. The Global Solutions segment delivers a comprehensive array of products and services tailored for healthcare providers and manufacturers. This includes a range of medical and surgical provisions, encompassing both well-known brands and O&M's own proprietary items. Additionally, this division offers crucial services to healthcare providers, such as supplier management, data analytics, inventory control, and clinical supply oversight. It also develops various programs to provide logistical support and marketing strategies for its network of suppliers. Conversely, the Global Products segment focuses on manufacturing and procuring medical and surgical items designed to prevent infections acquired in healthcare settings, serving both acute care facilities and alternative site channels. Its diverse product portfolio features sterilization wraps, surgical drapes and gowns, facial protection gear, various protective apparel, medical examination gloves, customized and minor procedure kits, among other essential medical supplies. O&M supplies its extensive range of offerings directly to a broad client base, which includes large multi-facility healthcare provider networks, independent hospitals, surgical centers, physician's practices, and hospital systems. Distribution also occurs indirectly through collaborations with third-party partners. Founded in 1882, the company maintains its principal corporate office in Richmond, Virginia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Aug 2, 2024 |
| $0.36+9.09% vs estimate |
| $2.67B+0.93% vs estimate |
| Q1 2024 | May 3, 2024 | $0.19+11.76% vs estimate | $2.61B+0.12% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
$9.57+$0.33 (+3.57%)
Sight Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.47% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$0.68+$0.00 (+0.46%)
Canopy Growth Corporation’s quoted price sits in the lower half of its reported 52-week range, 71.64% below the high.
$1.59+$0.07 (+4.28%)
Cabaletta Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.53% below the high.
$2.66-$0.03 (-1.12%)
High Tide Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.02% below the high.
$5.94$0.00 (0.0%)
BioAge Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.12% below the high.
